Steffen Borrmann

List of Publications by Year
in descending order

97	5,532	66343	85541
papers	citations	42 h-index	71 g-index

99	99	99	5619
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature, 2012, 487, 375-379.	27.8	450
2	Longâ€Term Treatment of Intestinal Helminths Increases Mite Skinâ€Test Reactivity in Gabonese Schoolchildren. Journal of Infectious Diseases, 2004, 189, 892-900.	4.0	305
3	Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet, The, 2002, 359, 1365-1372.	13.7	259
4	Fosmidomycin for malaria. Lancet, The, 2002, 360, 1941-1942.	13.7	219
5	In Vitro Activities of Piperaquine, Lumefantrine, and Dihydroartemisinin in Kenyan Plasmodium falciparum Isolates and Polymorphisms in p fcrt and p fmdr1. Antimicrobial Agents and Chemotherapy, 2009, 53, 5069-5073.	3.2	140
6	Chloroquine resistance before and after its withdrawal in Kenya. Malaria Journal, 2009, 8, 106.	2.3	136
7	Fosmidomycinâ€Clindamycin for the Treatment ofPlasmodium falciparumMalaria. Journal of Infectious Diseases, 2004, 190, 1534-1540.	4.0	132
8	Fosmidomycin for the treatment of malaria. Parasitology Research, 2003, 90, S71-S76.	1.6	131
9	A barcode of organellar genome polymorphisms identifies the geographic origin of Plasmodium falciparum strains. Nature Communications, 2014, 5, 4052.	12.8	130
10	Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet, The, 2000, 355, 2041-2045.	13.7	126
11	Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial. PLoS ONE, 2009, 4, e7871.	2.5	125
12	Natural Immunization Against Malaria: Causal Prophylaxis with Antibiotics. Science Translational Medicine, 2010, 2, 40ra49.	12.4	118
13	Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet, The, 2008, 372, 1819-1827.	13.7	117
14	Randomized controlled trial of a traditional preparation of Artemisia annua L. (Annual Wormwood) in the treatment of malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004, 98, 318-321.	1.8	116
15	A micro-epidemiological analysis of febrile malaria in Coastal Kenya showing hotspots within hotspots. ELife, 2014, 3, e02130.	6.0	115
16	Fosmidomycin plus Clindamycin for Treatment of Pediatric Patients Aged 1 to 14 Years with Plasmodium falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2006, 50, 2713-2718.	3.2	112
17	The Prevalence of Parasite Infestation and House Dust Mite Sensitization in Gabonese Schoolchildren. International Archives of Allergy and Immunology, 2001, 126, 231-238.	2.1	111
18	Fosmidomycinâ€Clindamycin forPlasmodium falciparumInfections in African Children. Journal of Infectious Diseases, 2004, 189, 901-908.	4.0	105

#	Article	IF	Citations
19	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	97
20	In-situ observations of young contrails â€“ overview and selected results from the CONCERT campaign. Atmospheric Chemistry and Physics, 2010, 10, 9039-9056.	4.9	93
21	Pyronaridineâ€“artesunate or dihydroartemisininâ€“piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet, The, 2018, 391, 1378-1390.	13.7	93
22	Artesunate and Praziquantel for the Treatment ofSchistosoma haematobiumInfections: A Doubleâ€Blind, Randomized, Placeboâ€Controlled Study. Journal of Infectious Diseases, 2001, 184, 1363-1366.	4.0	91
23	Declining Responsiveness of Plasmodium falciparum Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast. PLoS ONE, 2011, 6, e26005.	2.5	87
24	Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in Plasmodium falciparum in Kenya. Scientific Reports, 2013, 3, 3318.	3.3	75
25	Short-Course Regimens of Artesunate-Fosmidomycin in Treatment of Uncomplicated Plasmodium falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2005, 49, 3749-3754.	3.2	74
26	NF135.C10: A New Plasmodium falciparum Clone for Controlled Human Malaria Infections. Journal of Infectious Diseases, 2013, 207, 656-660.	4.0	72
27	Computational Prediction of Host-Parasite Protein Interactions between P. falciparum and H. sapiens. PLoS ONE, 2011, 6, e26960.	2.5	72
28	Atovaquone/Proguanil. Drugs, 2003, 63, 597-623.	10.9	71
29	Artesunate-Clindamycin versus Quinine-Clindamycin in the Treatment ofPlasmodium falciparum Malaria: A Randomized Controlled Trial. Clinical Infectious Diseases, 2005, 40, 1777-1784.	5.8	64
30	Population Genetic Analysis of Plasmodium falciparum Parasites Using a Customized Illumina GoldenGate Genotyping Assay. PLoS ONE, 2011, 6, e20251.	2.5	63
31	Whole-Genome Scans Provide Evidence of Adaptive Evolution in Malawian Plasmodium falciparum Isolates. Journal of Infectious Diseases, 2014, 210, 1991-2000.	4.0	62
32	Assessment of Volume Depletion in Children with Malaria. PLoS Medicine, 2004, 1, e18.	8.4	58
33	Chlorproguanilâ^'Dapsoneâ^'Artesunate versus Artemetherâ^'Lumefantrine: A Randomized, Double-Blind Phase III Trial in African Children and Adolescents with Uncomplicated Plasmodium falciparum Malaria. PLoS ONE, 2009, 4, e6682.	2.5	58
34	Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infectious Diseases, The, 2016, 16, 189-198.	9.1	58
35	Vaccineâ€Like Immunity against Malaria by Repeated Causalâ€Prophylactic Treatment of Liverâ€StagePlasmodiumParasites. Journal of Infectious Diseases, 2009, 199, 899-903.	4.0	55
36	Variable lifetimes and loss mechanisms for NO₃ and N₂O₅ during the DOMINO campaign: contrasts between marine, urban and continental air. Atmospheric Chemistry and Physics, 2011, 11, 10853-10870.	4.9	55

#	Article	IF	Citations
37	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	51
38	Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. PLoS Medicine, 2017, 14, e1002212.	8.4	50
39	Novel approaches to whole sporozoite vaccination against malaria. Vaccine, 2015, 33, 7462-7468.	3.8	48
40	Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. Malaria Journal, 2015, 14, 359.	2.3	47
41	Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. PLoS Medicine, 2018, 15, e1002579.	8.4	47
42	In Vitro Activity of Antifolate and Polymorphism in Dihydrofolate Reductase ofPlasmodium falciparumIsolates from the Kenyan Coast: Emergence of Parasites with Ile-164-Leu Mutation. Antimicrobial Agents and Chemotherapy, 2009, 53, 3793-3798.	3.2	46
43	Aerosol layers from the 2008 eruptions of Mount Okmok and Mount Kasatochi: In situ upper troposphere and lower stratosphere measurements of sulfate and organics over Europe. Journal of Geophysical Research, 2010, 115, .	3.3	46
44	Immune Responses Induced by Repeated Treatment Do Not Result in Protective Immunity toSchistosoma haematobium:Interleukin (IL)â€“5 and ILâ€10 Responses. Journal of Infectious Diseases, 2002, 186, 1474-1482.	4.0	45
45	Reassessment of the resistance of Plasmodium falciparum to chloroquine in Gabon: implications for the validity of tests in vitro vs. in vivo. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2002, 96, 660-663.	1.8	45
46	Clinical and Parasitological Characteristics of Puerperal Malaria. Journal of Infectious Diseases, 2005, 191, 1005-1009.	4.0	44
47	The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem^{Â®}) for acute uncomplicatedPlasmodium falciparummalaria. Tropical Medicine and International Health, 2010, 15, 434-41.	2.3	42
48	Preferential Invasion by Plasmodium Merozoites and the Self-Regulation of Parasite Burden. PLoS ONE, 2013, 8, e57434.	2.5	40
49	Defining Clinical Malaria: The Specificity and Incidence of Endpoints from Active and Passive Surveillance of Children in Rural Kenya. PLoS ONE, 2010, 5, e15569.	2.5	40
50	In Vitro Activities of Quinine and Other Antimalarials and pfnhe Polymorphisms in Plasmodium Isolates from Kenya. Antimicrobial Agents and Chemotherapy, 2010, 54, 3302-3307.	3.2	39
51	Short-Course Artesunate Treatment of Uncomplicated Plasmodium falciparum Malaria in Gabon. Antimicrobial Agents and Chemotherapy, 2003, 47, 901-904.	3.2	35
52	High Prevalence of Human Antibodies to Recombinant Duffy Binding-Like Î± Domains of the Plasmodium falciparum -Infected Erythrocyte Membrane Protein 1 in Semi-Immune Adults Compared to That in Nonimmune Children. Infection and Immunity, 2001, 69, 7603-7609.	2.2	32
53	Induction of Antimalaria Immunity by Pyrimethamine Prophylaxis during Exposure to Sporozoites Is Curtailed by Parasite Resistance. Antimicrobial Agents and Chemotherapy, 2011, 55, 2760-2767.	3.2	31
54	Targeting Plasmodium liver stages: better late than never. Trends in Molecular Medicine, 2011, 17, 527-536.	6.7	30

#	Article	IF	Citations
55	Atovaquone and Proguanil versus Amodiaquine for the Treatment of Plasmodium falciparum Malaria in African Infants and Young Children. Clinical Infectious Diseases, 2003, 37, 1441-1447.	5.8	29
56	Antibody Responses toPlasmodium falciparumMerozoite Surface Proteinâ€“1 and Efficacy of Amodiaquine in Gabonese Children withP. falciparumMalaria. Journal of Infectious Diseases, 2003, 187, 1137-1141.	4.0	27
57	Delayed parasite elimination in human infections treated with clindamycin parallels â€˜delayed deathâ€™ of Plasmodium falciparum in vitro. International Journal for Parasitology, 2007, 37, 777-785.	3.1	27
58	SHORT REPORT: PILOTING PAPERLESS DATA ENTRY FOR CLINICAL RESEARCH IN AFRICA. American Journal of Tropical Medicine and Hygiene, 2005, 72, 301-303.	1.4	27
59	Transmission of Cryptosporidium Species Among Human and Animal Local Contact Networks in Sub-Saharan Africa: A Multicountry Study. Clinical Infectious Diseases, 2021, 72, 1358-1366.	5.8	26
60	Pharmacokinetic and Pharmacodynamic Characteristics of a New Pediatric Formulation of Artemether-Lumefantrine in African Children with Uncomplicated Plasmodium falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2011, 55, 3994-3999.	3.2	24
61	Spatial Distribution of Bednet Coverage under Routine Distribution through the Public Health Sector in a Rural District in Kenya. PLoS ONE, 2011, 6, e25949.	2.5	24
62	In Vivo and In Vitro Efficacy of Amodiaquine againstPlasmodium falciparumin an Area of Continued Use of 4â€Aminoquinolines in East Africa. Journal of Infectious Diseases, 2009, 199, 1575-1582.	4.0	23
63	PlasmoView: A Web-based Resource to Visualise Global Plasmodium falciparum Genomic Variation. Journal of Infectious Diseases, 2014, 209, 1808-1815.	4.0	23
64	Lactic Acidosis in Gabonese Children with Severe Malaria Is Unrelated to Dehydration. Clinical Infectious Diseases, 2006, 42, 1719-1725.	5.8	21
65	Differential activity of methylene blue against erythrocytic and hepatic stages of Plasmodium. Malaria Journal, 2018, 17, 143.	2.3	20
66	Polymorphisms in the parasite genes for pfcrt and pfmdr-1 as molecular markers for chloroquine resistance in Plasmodium falciparum in LambarÃ©nÃ©, Gabon. Parasitology Research, 2002, 88, 475-476.	1.6	19
67	Protection against malaria by immunization with non-attenuated sporozoites under single-dose piperaquine-tetraphosphate chemoprophylaxis. Vaccine, 2014, 32, 6005-6011.	3.8	18
68	Dihydroartemisinin-Piperaquine vs. Artemether-Lumefantrine for First-Line Treatment of Uncomplicated Malaria in African Children: A Cost-Effectiveness Analysis. PLoS ONE, 2014, 9, e95681.	2.5	18
69	Effects of Plasmodium falciparum Parasite Population Size and Patient Age on Early and Late Parasitological Outcomes of Antimalarial Treatment in Children. Antimicrobial Agents and Chemotherapy, 2008, 52, 1799-1805.	3.2	16
70	Protective immunity against malaria by â€˜natural immunizationâ€™: a question of dose, parasite diversity, or both?. Current Opinion in Immunology, 2011, 23, 500-508.	5.5	16
71	Arrested Plasmodium liver stages as experimental anti-malaria vaccines. Hum Vaccin, 2011, 7, 16-21.	2.4	16
72	Nitric oxide generation in children with malaria and the NOS2G-954C promoter polymorphism. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 299, R1248-R1253.	1.8	15

#	Article	IF	Citations
73	Evidence for the efficacy of artesunate in asymptomatic Plasmodium malariae infections. Journal of Antimicrobial Chemotherapy, 2002, 50, 751-754.	3.0	14
74	Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria. PLoS Medicine, 2008, 5, e227.	8.4	14
75	Comparative genomics revealed adaptive admixture in Cryptosporidium hominis in Africa. Microbial Genomics, 2021, 7, .	2.0	13
76	Elevated Plasmodium sporozoite infection and multiple insecticide resistance in the principal malaria vectors Anopheles funestus and Anopheles gambiae in a forested locality close to the YaoundÃ© airport, Cameroon. Wellcome Open Research, 2020, 5, 146.	1.8	10
77	Age-dependent enhancement of IFN-Î³ responses to Plasmodium falciparum liver stage antigen-1 T cell epitopes. Parasitology Research, 2002, 88, 1083-1089.	1.6	8
78	Severe malaria in a splenectomised Gabonese woman. Wiener Klinische Wochenschrift, 2003, 115, 63-65.	1.9	8
79	An Economic Evaluation of the Posttreatment Prophylactic Effect of Dihydroartemisininâ€“Piperaquine Versus Artemetherâ€“Lumefantrine for First-Line Treatment of Plasmodium falciparum Malaria Across Different Transmission Settings in Africa. American Journal of Tropical Medicine and Hygiene, 2015, 93, 961-966.	1.4	8
80	Controlled Human Malaria Infection (CHMI) Studies: Over 100 Years of Experience with Parasite Injections. Methods in Molecular Biology, 2019, 2013, 91-101.	0.9	8
81	Antimalarial activity of isoquine against Kenyan Plasmodium falciparum clinical isolates and association with polymorphisms in pfcrt and pfmdr1 genes. Journal of Antimicrobial Chemotherapy, 2013, 68, 786-788.	3.0	6
82	Temporal Association of Acute Hepatitis A and Plasmodium falciparum Malaria in Children. PLoS ONE, 2011, 6, e21013.	2.5	6
83	SHORT REPORT: EVALUATION OF A SIMPLE AND INEXPENSIVE PHOTOMETRIC DEVICE FOR THE MEASUREMENT OF HEMOGLOBIN. American Journal of Tropical Medicine and Hygiene, 2004, 71, 691-692.	1.4	6
84	Molecular surveillance and genetic divergence of rotavirus A antigenic epitopes in Gabonese children with acute gastroenteritis. EBioMedicine, 2021, 73, 103648.	6.1	6
85	Drug-induced hypersensitivity to artemisinin-based therapies for malaria. Trends in Parasitology, 2022, 38, 136-146.	3.3	5
86	P. falciparum msp1 and msp2 genetic diversity in P. falciparum single and mixed infection with P. malariae among the asymptomatic population in Southern Benin. Parasitology International, 2022, 89, 102590.	1.3	5
87	Lack of multiple copies of pfmdr1 gene in Papua New Guinea. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, 1151-1153.	1.8	4
88	Surveillance of Plasmodium malariae infection among inhabitants of rural areas in Ouidahâ€“Kpomasseâ€“Tori Bossito health district, Benin. Parasitology Research, 2022, 121, 275-286.	1.6	3
89	Efficacy, T cell activation and antibody responses in accelerated Plasmodium falciparum sporozoite chemoprophylaxis vaccine regimens. Npj Vaccines, 2022, 7, .	6.0	3
90	High ESBL-E colonization rate among children in Gabon: a follow-up study. Journal of Medical Microbiology, 2021, 70, .	1.8	2

#	Article	IF	Citations
91	Short report: evaluation of a simple and inexpensive photometric device for the measurement of hemoglobin. American Journal of Tropical Medicine and Hygiene, 2004, 71, 691-2.	1.4	2
92	Pharmacokinetic and Pharmacodynamic Characteristics of a New Pediatric Formulation of Artemether-Lumefantrine in African Children with Uncomplicated Plasmodium falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2012, 56, 5429-5429.	3.2	1
93	Plasmodium falciparum variant erythrocyte surface antigens: a pilot study of antibody acquisition in recurrent natural infections. Malaria Journal, 2017, 16, 450.	2.3	1
94	Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis. Malaria Journal, 2022, 21, 106.	2.3	1
95	Reply to Mikolajczak et al. Journal of Infectious Diseases, 2010, 201, 1271-1272.	4.0	0
96	Fosmidomycin as an Antimalarial Agent. , 2012, , 119-137.		0
97	JMM - Past and Present. Journal of Molecular Medicine, 2002, 80, 327-328.	3.9	0